disease treatment

A change of continuation phase tuberculosis (TB) treatment regimen from ethambutol (E) and isoniazid (H) combination for 6 months (6EH) to rifampicin (R) and isoniazid (H) combination for 4 months (4RH) was recommended. However, the effect of the regimen switch in the Ethiopian setting is not known. A comparative cross-sectional study among 790 randomly selected new cases of TB (395 each treated with 4RH and 6EH during the continuation phase) was conducted in nine health centers and one hospital in three zones in southwestern Ethiopia. The switch of continuation phase TB treatment regimen from 6EH to 4RH has brought better treatment outcomes which imply applicability of the recommendation in high prevalent and resource constrained settings. Therefore, it should be maintained and augmented through further studies on its impact among the older, rural residents and HIV positives.

 In 2013 the Global Drug Facility reduced the price of the second-line drugs it supplies for multidrug-resistant tuberculosis (MDR TB): the overall cost of the longest and most expensive treatment regimen for a patient decreased by 26%, from US$7,890 in 2011 to US$5,822 in 2013. The price of treatment for MDR TB was reduced by consolidating orders to achieve large purchase volumes, by international, competitive bidding and by the existence of donor-funded medicine stockpiles. The rise in the number of suppliers of internationally quality-assured drugs was also important. The savings achieved from lower drug costs could be used to increase the number of patients on high-quality treatment.

Printer Friendly Version
Subscribe to RSS - disease treatment